Eli Lilly Retatrutide Early Access: Who Qualifies and How (2026)

Eli Lilly retatrutide early access is real. It is also tiny.

If you've been watching retatrutide's trial numbers climb and wondering why you can't simply ask your doctor for it, you're not alone. Plenty of people asked the same thing in August, when Lilly confirmed that a drug it had quietly given to one patient could now be requested for others. The path exists. But it was built for a very specific kind of patient, it runs through your doctor rather than you, and most people who read the headlines will not fit through it.

Below, we'll go through what Lilly actually announced, the exact eligibility wording, how a doctor applies step by step, what it costs, the honest odds, and what to do if you don't qualify.

What Eli Lilly Announced on August 3, 2026

It started with one patient.

In April 2026, Lilly quietly gave retatrutide to a single 79-year-old patient outside its trials, a case AJMC reports was referred by the NIH. STAT broke the story on June 23. Within weeks, obesity doctors were asking the obvious question: if one patient can get it, why can't mine? Several said they had applied for patients and heard nothing for weeks.

On Monday, August 3, Lilly answered. A spokesperson told STAT that "for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial," the company believes it is medically appropriate to make retatrutide available before FDA approval, and that it is reviewing requests from health care providers.

The paperwork behind that statement already existed. Lilly had registered a single-patient expanded access protocol, "Pre-approval Expanded Access of Retatrutide (LY3437943)," on ClinicalTrials.gov as NCT07629401. It was first posted on June 5, 2026, and the full criteria were added in an update submitted on August 3. Its status reads "Available." That record, plus a Lilly Medical page last reviewed on August 26, is the closest thing to a rulebook. Early news coverage disagreed on the details for a few days; these two Lilly documents settle it.

Eli Lilly Retatrutide Early Access Criteria: The Five Gates

Every gate is mandatory.

The registry entry says "All of the following criteria must be met." Here is each one in Lilly's words, with our plain-English reading next to it.

There is one exclusion: a medical contraindication to retatrutide. Lilly doesn't list those publicly yet because the drug has no label, but the warnings that apply to GLP-1 drugs in general (a personal or family history of medullary thyroid cancer or MEN2, prior pancreatitis, pregnancy) are where a doctor would start.

Gate 2 is the one that trips people up. Some early reports said "highest approved dose." Lilly's own documents say "highest available dose" of chronic weight management therapy, plus a hard BMI floor of 35. In practice that means you have already tried something like tirzepatide at 15 mg or semaglutide at its top weight-loss dose, stayed on it, tolerated it, and still sit at a BMI of 35 or above. Someone who quit Zepbound at 5 mg because of nausea has not met that bar.

Expanded Access, Compassionate Use, Early Access: Same Thing?

Yes, mostly.

"Expanded access" is FDA's term. Lilly's own policy page says expanded access is "also known as compassionate use." News outlets called it early access. All three mean the same thing here: an unapproved drug given to one patient outside a trial, with FDA and an ethics board signing off. So if you searched for Eli Lilly retatrutide compassionate use, this is the same program.

What it is not: the federal Right to Try Act of 2018. Right to Try skips FDA review, but it requires a "life-threatening disease or condition," and FDA notes the law "does not require a sponsor to provide" the drug. Lilly has chosen to handle retatrutide through expanded access, so that is the door to knock on.

How a Doctor Applies for Retatrutide Expanded Access

Your role ends at step one.

Lilly says patients and caregivers should contact their treating physician, not Lilly. From there, the process combines Lilly's steps with FDA's single-patient rules:

1. The doctor calls Lilly. The Lilly Answers Center at 1-800-LillyRx (1-800-545-5979) takes expanded access requests.
2. Lilly screens and sends an intake form. If the patient appears to meet the initial criteria, Lilly's medical team sends a detailed intake form.
3. Lilly decides. Lilly's general expanded access policy says it responds "in no more than five business days" once it has the request and the required medical information. Doctors in August reported waiting much longer, likely because that clock starts only when the file is complete.
4. The doctor signs a letter of agreement with Lilly and receives a letter of authorization (LOA) that lets FDA reference Lilly's drug file.
5. The doctor files with FDA. For a single non-emergency patient this is Form FDA 3926, submitted with the LOA through FDA's Expanded Access eRequest system or by mail. Treatment may begin 30 days after FDA receives it, or sooner if FDA says so.
6. An ethics board approves. An institutional review board (IRB) must sign off. On Form 3926, the doctor can ask to use review by the IRB chair or one designated member instead of a full convened meeting.
7. You sign informed consent on an IRB-approved form.
8. Lilly ships to the doctor, never to you. The doctor stores the drug cold, dispenses it, handles returns, reports adverse events and files a final report.

Step 8 is the one that catches doctors off guard. The physician becomes the sponsor of an investigational new drug application for one patient, with the record-keeping and safety reporting that comes with it. Large academic obesity clinics do this routinely. A busy primary care office or a telehealth prescriber may not have the time, the IRB relationship or the cold-chain setup, and that alone ends many requests before they start.

How Much Does Retatrutide Early Access Cost?

The drug itself: nothing.

Lilly's Medical page states that it provides retatrutide at no cost through the expanded access program. The August news coverage didn't report a price; the no-cost line appears on Lilly's page, last reviewed August 26.

Free drug doesn't mean free treatment. Expect to pay for the visits, labs and monitoring your doctor requires, plus any fee an independent IRB charges. Whether insurance covers visits tied to an investigational drug depends on your plan. Ask before the paperwork starts, not after.

Realistic Odds: Who Actually Gets It

7x Quality Tested Bac Water

Don't ruin a $300 peptide on generic bac water.

Sterile, non-pyrogenic, exactly 0.9% benzyl alcohol, with a COA on every batch. Made for peptide reconstitution, not repackaged from generic stock.

0.9% benzyl alcohol 7x tested in USA COA every batch

Get PureBac bac water From $7.99 · Free shipping over $150

Top Pick R-30 (Retatrutide 30mg) R-30 (Retatrutide 30mg) from Ascension Peptides. The current batch was tested by Kovera Labs at 99.832% purity, and it ships from the US. Exclusive 50% off — use code PEPTIDEDECK

Get R-30 (Retatrutide 30mg)

Nobody has published a number.

As of October 19, 2026, Lilly has not said how many requests it has received or approved. The only confirmed patient is still the 79-year-old from April. Lilly's language points to small numbers: "a limited number of patients," decided "case-by-case," with availability depending on "geography, product supply, and detailed individual eligibility assessment."

Lilly's general expanded access policy adds two tests on top of the retatrutide criteria. The expected benefit must outweigh the known or anticipated risks. And providing the drug "will not interfere with the initiation, conduct, or completion of clinical trials." With a Biologics License Application still ahead, protecting the trial program will come first.

Here's our honest read. A patient with a BMI of 42, coronary artery disease and sleep apnea, who plateaued on tirzepatide 15 mg for a year and lives hours from any trial site, has a real shot if a specialist files carefully. A patient with a BMI of 33 who wants to switch from Zepbound because a friend lost more on reta has essentially none. Most readers sit closer to the second profile than the first.

The Trial Route Is Smaller Than You Think

We checked the registry.

Gate 4 says you must be unable to join a retatrutide trial. So how many are open? A ClinicalTrials.gov search for retatrutide on October 19, 2026 returned 32 Lilly-sponsored records: 21 completed, 9 active but not recruiting, the expanded access protocol, and exactly one trial recruiting. That trial, SYNERGY-Outcomes (NCT07165028), studies tirzepatide and retatrutide in fatty liver disease, and it requires liver fat of at least 8% plus liver stiffness and blood markers in a set range. It lists 563 locations, but it is not an obesity trial most readers will qualify for.

That cuts both ways. If you have obesity without that kind of liver disease, there is likely no retatrutide trial you can join right now, which helps you meet gate 4. It does nothing for the other four gates. Our retatrutide clinical trials guide tracks every study and what each one requires, so check it before assuming the trial door is closed.

Early Access vs the FDA Approval Timeline

Early access has an expiry date.

Lilly says expanded access programs are phased out once a medicine is approved and on the market. When that happens depends on the filing. On July 23, 2026, Lilly said it plans to submit its BLA in the first quarter of 2027, later than it had previously indicated, because the manufacturing and quality package needed more time. An FDA decision typically takes about 10 to 12 months after filing, which puts approval in late 2027 at the earliest and more likely 2028.

So expanded access covers a window of roughly 12 to 24 months for the few people who get in. The full data keeps arriving in the meantime. The TRIUMPH-2 trial in people with type 2 diabetes was published in The Lancet on September 29, with average weight loss of 12.7%, 19.1% and 20.8% at 4, 9 and 12 mg after 80 weeks, against 4.0% on placebo (Lilly's efficacy estimand); our TRIUMPH-2 breakdown covers the side effects too. For the approval question itself, including what could speed it up or slow it down, see our retatrutide FDA approval timeline.

What's Changed Since August

Less than you'd hope.

• August 26: Lilly's Medical page, reviewed that day, spells out the BMI 35 floor, the no-cost statement and the sponsor duties described above.
• September 11: Lilly dropped one of the six lawsuits it filed on August 12, against Aesthetic Envy Cosmetic Centers, with prejudice and without public terms.
• September 29: TRIUMPH-2 full results in The Lancet.
• October 8: Lilly filed five more lawsuits against retatrutide sellers, including LiveWell Peptides in the Northern District of Texas. The complaint states that retatrutide "cannot legally be sold for human use to anyone, anywhere, for any reason."
• October 15: The Atlanta Journal-Constitution reported more than 70 FDA adverse event reports involving retatrutide since 2024, including four deaths this year. Those reports are unverified and don't show the drug caused the harm. Outside trials and expanded access, none of it can be Lilly's product. Our guide on whether retatrutide is safe puts the trial safety data next to these reports.

What hasn't changed: no new eligibility rules, no public approval count, and no wider program.

If You Don't Qualify for Early Access

Most people won't. If you're asking how to get retatrutide early anyway, these are the real options.

1. Get the most out of an approved drug first

Here's the part most articles skip. The road to early access runs straight through Zepbound and Wegovy, because gate 2 requires you to have failed the top dose of one. If you haven't reached that dose, that's your next step either way. Tirzepatide 15 mg produced 20.9% average weight loss at 72 weeks in SURMOUNT-1, and semaglutide 2.4 mg produced 14.9% at 68 weeks in STEP 1. Those drugs come with a label, insurance pathways and years of safety data. If you're already on tirzepatide and want to understand how the two compare, see retatrutide vs tirzepatide.

2. Watch for new trials

Lilly will keep running retatrutide studies after filing. New obesity or heart and kidney trials can open with little notice, and a trial gets you the real drug (or placebo) under close monitoring at no cost.

3. Understand the gray market before you touch it

This is where many people end up, so let's be plain about it. FDA's June 2026 statement says retatrutide "cannot be used in compounding under federal law" and has "not been found safe and effective for any condition," and the agency has warned telehealth companies for marketing it. Lilly calls every consumer sale illegal and has filed eleven lawsuits against sellers since August. No compounding pharmacy or telehealth service can legally prescribe or fill it.

People who buy reta vials anyway are taking on the quality risk themselves, and the batch is everything. At minimum, ask for a lab report for the exact batch showing HPLC purity, net content in milligrams and an identity test by mass spectrometry, plus endotoxin and sterility screens. A vial without that report is a guess. If you're weighing that route, our guide on where to buy retatrutide explains how to read those reports and spot red flags, and our retatrutide for sale page lists current vial prices: the Ascension R-30 (30 mg) is $250, or $125 with code PEPTIDEDECK, and the R-10 is $100, or $50 with the code. PeptideDeck may earn a commission on those links. Switching from a prescribed drug without supervision is where most problems start; our tirzepatide to retatrutide switching guide covers dose overlap and timing, and none of it replaces a doctor who knows your history.

How the four routes compare

For a fuller walkthrough of every legal and practical route in one place, see how to get retatrutide in 2026.

Frequently Asked Questions

Sources

1. Lilly Medical (US). Is there an expanded access program for retatrutide? Last reviewed August 26, 2026.
2. ClinicalTrials.gov. NCT07629401: Pre-approval Expanded Access of Retatrutide (LY3437943). Eli Lilly and Company. First posted June 5, 2026; updated August 6, 2026.
3. Eli Lilly and Company. Expanded access (policy, threshold criteria and response time).
4. STAT. Eli Lilly to offer retatrutide access given earlier to just one patient. August 3, 2026.
5. AJMC. Lilly Expands Retatrutide Access Amid Doctor Pushback. August 5, 2026.
6. U.S. FDA. Expanded Access: How to Submit a Request (Forms).
7. U.S. FDA. Expanded Access: Information for Physicians.
8. U.S. FDA. Right to Try.
9. U.S. FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. June 2026.
10. BioSpace. Lilly preps FDA run for triple G weight loss drug with phase 3 data. July 2026.
11. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315.
12. Eli Lilly and Company (via Placera). TRIUMPH-2 results press release. September 29, 2026 (simultaneous Lancet publication).
13. Healio. Eli Lilly files lawsuits against six companies for allegedly selling retatrutide. August 14, 2026.
14. Eli Lilly and Company v. Brown (d/b/a LiveWell Peptides), N.D. Tex. No. 3:26-cv-03514, Complaint, filed October 8, 2026.
15. Eli Lilly and Company v. Aesthetic Envy Cosmetic Centers LLC, E.D. Cal. No. 2:26-cv-02764, Notice of voluntary dismissal, September 11, 2026.
16. The Atlanta Journal-Constitution. Knockoff versions of this unapproved weight loss drug are being openly sold in Georgia. October 15, 2026.
17. ClinicalTrials.gov. NCT07165028: SYNERGY-Outcomes, and a registry search for "retatrutide" run October 19, 2026.
18. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID 35658024.
19. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID 33567185.